Journal of Neuro-Oncology

, Volume 29, Issue 2, pp 149–155 | Cite as

Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines

  • Bertrand C. Liang
Laboratory Investigation


Recurrent gliomas are most often treated by chemotherapy. However, these tumors typically acquire resistance to most drugs administered, and patients will usually die of recurrent tumor. Factors which may play a role include overexpression of putative multidrug resistance genes, such as the multidrug resistance gene 1 (MDR1), multidrug resistance associated protein gene (MRP), 06-alkylguanine, DNA alkyltransferase gene (06MT) and excision repair cross complementing gene 1(ERCCl). Tumor hypoxia has also been shown to be associated with drug resistance in other soft tissue tumors. Since gliomas have regions of diminished oxygenation, and have clinical resistance to chemotherapy, the relationship between phenotypic resistance to chemotherapy after hypoxic exposure and expression of drug resistance genes was investigated in glioma cell lines (U373 MG, PFAT-MT). After a 24 hour exposure to hypoxia, drugs 1, 3-bis, 2-chloroethyl-1-nitrosurea (BCNU) and cis-diammine, dichloroplatinum II (CDDP) were administered, and cell survival was determined. Hypoxic exposure was associated with increased survival of the cell lines after administration of BCNU and CDDP, with resistance to BCNU 15 to 30-fold when compared to cells which did not undergo hypoxic exposure. Both tumor cell lines also showed some degree of resistance to CDDP, although not to the extent of BCNU (2 to 3-fold increased resistance). The expression of the drug resistance genes was found to be unchanged when comparing cells which had undergone hypoxic exposure and those which had not. Thus, hypoxic exposure is associated with substantial drug resistance in brain tumor cell lines. The lack of correlation between the induced phenotype and known drug resistance genes suggests other mechanisms may be acting in these tumors in hypoxic conditions.

Key words

glioblastoma BCNU cis-platinum drug therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35:219–226,1985Google Scholar
  2. 2.
    Walker MD, Green SB, Byar DP, Alexander E, Betzdorf U, Brooks WH, Hunt WE, MacCarty M: Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant gliomas after surgery. New Eng J Med303:1323–1329, 1980Google Scholar
  3. 3.
    Feun LG, Savaraj N, Landy H: Drug resistance in brain tumors. J Neurone 20:165–176,1994Google Scholar
  4. 4.
    Endicott JA, Ling V: The biochemistry of P-Glycoproteinmediated multidrug resistance. Annu Rev Biochem 58:137–171, 1989CrossRefPubMedGoogle Scholar
  5. 5.
    Cole SPC, Nhardaj C, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654, 1992PubMedGoogle Scholar
  6. 6.
    Rosenblum ML, Gerosa MA, Bodell WJ, Talcott RL: Tumor cell resistance. In: Progress in Experimental Research, Volume 27, pp 191–211. Karger Publishers, Basel, 1984Google Scholar
  7. 7.
    Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate to response to platinum based chemotherapy. J Clin Invest 94:703–708,1994Google Scholar
  8. 8.
    Dabholkar M, Bostick-Bruton R, Reed E: ERCC1 and ERCC2 expression in fresh human tumor tissues. J Natl Cancer Inst 84:1512–1517,1992Google Scholar
  9. 9.
    Teicher BA: Hypoxia and drug resistance. Cane Metas Rev 13:139–168,1994Google Scholar
  10. 10.
    Shapiro WR, Shapiro JR: Principles of brain tumor chemotherapy. Semin Oncol 13:56–69,1986Google Scholar
  11. 11.
    Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E: Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N, N′, N″-triethylenethiophosphoramide. Cancer Res 49:4996–5001,1989Google Scholar
  12. 12.
    Rice GC, Ling V, Shimke RT: Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci 84:9261–9264,1987PubMedGoogle Scholar
  13. 13.
    Schlappack OK, Zimmermann A, Hill RP: Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumor cells. Br J Cancer 64:663–670,1991Google Scholar
  14. 14.
    Wilson RE, Keng PC, Sutherland RM: Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Nall Cancer Inst 81:1235–1240,1989Google Scholar
  15. 15.
    Wilson RE, Talley RD, Storch TG:Oxygen concentration regulated EGF-induced proliferation and EGFR down regulation. Biochim Biophys Res Commun 153: 952–958, 1988Google Scholar
  16. 16.
    Deguchi Y, Negoro S, Kishimoto S: c-fos expression in human skin fibroblasts by reperfusion after oxygen deficiency: a recovery change of human skin fibroblasts after oxygen deficiency stress. Biochim Biophys Res Commun 149:1093–1098, 1987Google Scholar
  17. 17.
    Young SD, Hill RP: Effects of reoxygenation of cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J Natl Cancer Inst 82:371–380, 1990Google Scholar
  18. 18.
    Rice GC, Hoy C, Schimke RT: Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci 83:5978–5982, 1986PubMedGoogle Scholar
  19. 19.
    Nakatsu Y, Hattori K, Hayakawa H, Shimizu K, Sekiguchi M:Organization and expression of the human gene for 06, m-methylguanine-DNA methyltransferase. Mut Res 293: 119–132,1993Google Scholar
  20. 20.
    Heacock CS, Sutherland RM: Enhanced synthesis of stress proteins caused by hypoxia and relation to altered cell growth and metabolism. Br J Cancer 62:217–225,1990Google Scholar
  21. 21.
    Sciandra JJ, Subjeck JR, Hughes CS: Induction of glucoseregulated proteins during anaerobic exposure and of heatshock proteins after reoxygenation. Proc Natl Acad Sci 81: 4843–4847,1984Google Scholar
  22. 22.
    Brown JM, Giaccia AJ: Tumor hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 65:95–102,1994Google Scholar
  23. 23.
    Yao KS, Clayton M, O'Dwyer PJ: Interaction of head and hypoxia modulating transcription of DT diaphorase in human colon adenocarcinoma cells. Cell Growth Differ 5:125–131, 1994Google Scholar
  24. 24.
    Shapiro WR: Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13:38–45, 1986Google Scholar
  25. 25.
    Nyce J: Drug-induced DNA hypermethylation and drug resistance in human tumors. Cane Res 49:5829–5836,1989Google Scholar
  26. 26.
    Bentivegna SS, Bresnick E: Inhibition of human 06-methylguanine-DNA methyltransferase by 5-methylcytosine. Cane Res 54:327–329,1994Google Scholar
  27. 27.
    Sakata K, Tak Kwok T, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM: Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64:809–814,1991Google Scholar
  28. 28.
    Bodell WJ, Tokuda K, Ludlum DB: Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-1-nitrosurea. Cane Res 48:4489–4492,1988Google Scholar
  29. 29.
    Hill DL, Kirk MC, Struck RF: Microsomal metabolism of nitrosureas. Cane Res 35:296–301,1975Google Scholar
  30. 30.
    Hill DL, N,N′-bis(2-chloroethyl)-N-nitrosurea, a substrate for glutathione (GSH) S-transferase. Proc Am Assoc Cane Res 17:52,1976Google Scholar
  31. 31.
    Talcott RE, Levin VA: Glutathione-dependent denitrosation of BCNU: Nitrite release catalyzed by mouse liver cytosol in vitro. Drug Metab Disappos 11:175–176,1983Google Scholar
  32. 32.
    Smith MT, Evans CG, Doane-Setzar P, Castro VM, Tahir MK, Mannervik B: Dentrosation of 1, 3-bis(2-chloroethyl) 1-nitrosurea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cane Res 49: 2621–2625,1989Google Scholar
  33. 33.
    Montaudon D, Bencherkroun MN, Londos-Gagliardi D, Robert J: Chromosomal modifications of a rat glioblastoma cell line during the acquisition and reversal of doxorubicin resistance. Anticanc Res 10:1667–1676,1990Google Scholar
  34. 34.
    Liang BC, Ross DA, Reed E: Genomic copy number changes of DNA repair genes ERCCI and ERCC2 in human gliomas. J Neuroonc, 26:17–231995Google Scholar
  35. 35.
    Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Miyaji K: Amplification and expression of a multidrug resistance gene in human glioma cell line. J Neurosurg 72:96–101,1990Google Scholar
  36. 36.
    Nabors MW, Griffin CA, Zehnbauer BA, Hruban RH, Phillips PC, Grossman SA, Brem H, Colvin OM: Multdrug resistance gene (MDR1) expression in human brain tumors. J Neurosurg 75:941–946, 1991Google Scholar
  37. 37.
    Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, Mori T, Hori S, Kohno K, Kuwano M: Possible involvement of multidrug-resistance associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide, and adriamycin in human glioma cells. Int J Cane 58:860–864,1994Google Scholar
  38. 38.
    Simon S, Roy D, Shindler M: Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci 91:1128–1132, 1994Google Scholar
  39. 39.
    Schneider E, Aftenberg GA, Cowen K: Increased intracellular pH as a possible mechanism of MRP-mediated mul tidrug resistance in the human mammary carcinoma cell line MCF7/VP. Proc Am Assoc Cane Res 36:325,1995Google Scholar
  40. 40.
    Bougnoux P, Chajes V, Hubert B, Germain E, Lhuillery C, Saez S, Calais G: n-3 polyunsaturated fatty acids and chemosensitivity of breast carcinoma. Proc Am Assoc Cane Res 36:327,1995Google Scholar
  41. 41.
    Owen R, Andrews PA, Murphy MP: Significant differences in DNA-binding proteins purified from MCF-7 adriamycin resistant versus sensitive breast carcinoma cell lines. Proc Am Assoc Cane Res 36:327,1995Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Bertrand C. Liang
    • 1
  1. 1.Clinical Pharmacology Branch, Division of Cancer Treatment, Clinical Oncology ProgramNational Cancer InstituteBethesdaUSA
  2. 2.DenverUSA

Personalised recommendations